Poseida Raises $30.5 Million in Series B Financing

SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced the company has raised $30.5 million in an oversubscribed Series B financing round, led by Longitude Capital. Additional new investors included Vivo Capital and the Tavistock Group, joined by existing investor Malin Corporation plc. In conjunction with the financing, David Hirsch, M.D., Ph.D., managing director at Longitude Capital, has joined Poseida’s Board of Directors.